Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction

Courtney Covert, Lili Ding, Darron Brown, Eduardo L. Franco, David I. Bernstein, Jessica A. Kahn

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Examination of cross-protection and type replacement after human papillomavirus (HPV) vaccine introduction is essential to guide vaccination recommendations and policies. The aims of this study were to examine trends in non-vaccine-type HPV: 1) genetically related to vaccine types (to assess for cross-protection) and 2) genetically unrelated to vaccine types (to assess for type replacement), among young women 13–26 years of age during the 11 years after HPV vaccine introduction. Participants were recruited from a hospital-based teen health center and a community health department for four cross-sectional surveillance studies between 2006 and 2017. Participants completed a survey that assessed sociodemographic characteristics and behaviors, and cervicovaginal swabs were collected and tested for 36 HPV genotypes. We determined changes in proportions of non-vaccine-type HPV prevalence and conducted logistic regression to determine the odds of infection across the surveillance studies, propensity-score adjusted to control for selection bias. Analyses were stratified by vaccination status. Among vaccinated women who received only the 4-valent vaccine (n = 1,540), the adjusted prevalence of HPV types genetically related to HPV16 decreased significantly by 45.8% (adjusted odds ratio [AOR] = 0.48, 95% confidence interval [CI] = 0.31–0.74) from 2006–2017, demonstrating evidence of cross-protection. The adjusted prevalence of HPV types genetically related to HPV18 did not change significantly (14.2% decrease, AOR = 0.83, 95% CI = 0.56–1.21). The adjusted prevalence of HPV types genetically unrelated to vaccine types did not change significantly (4.2% increase, AOR = 1.09, CI = 0.80–1.48), demonstrating no evidence of type replacement. Further studies are needed to monitor for cross-protection and possible type replacement after introduction of the 9-valent HPV vaccine.

Original languageEnglish (US)
Pages (from-to)1962-1969
Number of pages8
JournalHuman Vaccines and Immunotherapeutics
Volume15
Issue number7-8
DOIs
StatePublished - Aug 3 2019

Fingerprint

Cross Protection
Papillomavirus Vaccines
Vaccines
Odds Ratio
Confidence Intervals
Vaccination
Community Health Centers
Propensity Score
Selection Bias
Cross-Sectional Studies
Logistic Models
Genotype
Infection

Keywords

  • Cross-protection
  • human papillomavirus
  • type-replacement

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction. / Covert, Courtney; Ding, Lili; Brown, Darron; Franco, Eduardo L.; Bernstein, David I.; Kahn, Jessica A.

In: Human Vaccines and Immunotherapeutics, Vol. 15, No. 7-8, 03.08.2019, p. 1962-1969.

Research output: Contribution to journalArticle

Covert, Courtney ; Ding, Lili ; Brown, Darron ; Franco, Eduardo L. ; Bernstein, David I. ; Kahn, Jessica A. / Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction. In: Human Vaccines and Immunotherapeutics. 2019 ; Vol. 15, No. 7-8. pp. 1962-1969.
@article{f3797d68c2654956bac723dcadcd9054,
title = "Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction",
abstract = "Examination of cross-protection and type replacement after human papillomavirus (HPV) vaccine introduction is essential to guide vaccination recommendations and policies. The aims of this study were to examine trends in non-vaccine-type HPV: 1) genetically related to vaccine types (to assess for cross-protection) and 2) genetically unrelated to vaccine types (to assess for type replacement), among young women 13–26 years of age during the 11 years after HPV vaccine introduction. Participants were recruited from a hospital-based teen health center and a community health department for four cross-sectional surveillance studies between 2006 and 2017. Participants completed a survey that assessed sociodemographic characteristics and behaviors, and cervicovaginal swabs were collected and tested for 36 HPV genotypes. We determined changes in proportions of non-vaccine-type HPV prevalence and conducted logistic regression to determine the odds of infection across the surveillance studies, propensity-score adjusted to control for selection bias. Analyses were stratified by vaccination status. Among vaccinated women who received only the 4-valent vaccine (n = 1,540), the adjusted prevalence of HPV types genetically related to HPV16 decreased significantly by 45.8{\%} (adjusted odds ratio [AOR] = 0.48, 95{\%} confidence interval [CI] = 0.31–0.74) from 2006–2017, demonstrating evidence of cross-protection. The adjusted prevalence of HPV types genetically related to HPV18 did not change significantly (14.2{\%} decrease, AOR = 0.83, 95{\%} CI = 0.56–1.21). The adjusted prevalence of HPV types genetically unrelated to vaccine types did not change significantly (4.2{\%} increase, AOR = 1.09, CI = 0.80–1.48), demonstrating no evidence of type replacement. Further studies are needed to monitor for cross-protection and possible type replacement after introduction of the 9-valent HPV vaccine.",
keywords = "Cross-protection, human papillomavirus, type-replacement",
author = "Courtney Covert and Lili Ding and Darron Brown and Franco, {Eduardo L.} and Bernstein, {David I.} and Kahn, {Jessica A.}",
year = "2019",
month = "8",
day = "3",
doi = "10.1080/21645515.2018.1564438",
language = "English (US)",
volume = "15",
pages = "1962--1969",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "7-8",

}

TY - JOUR

T1 - Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction

AU - Covert, Courtney

AU - Ding, Lili

AU - Brown, Darron

AU - Franco, Eduardo L.

AU - Bernstein, David I.

AU - Kahn, Jessica A.

PY - 2019/8/3

Y1 - 2019/8/3

N2 - Examination of cross-protection and type replacement after human papillomavirus (HPV) vaccine introduction is essential to guide vaccination recommendations and policies. The aims of this study were to examine trends in non-vaccine-type HPV: 1) genetically related to vaccine types (to assess for cross-protection) and 2) genetically unrelated to vaccine types (to assess for type replacement), among young women 13–26 years of age during the 11 years after HPV vaccine introduction. Participants were recruited from a hospital-based teen health center and a community health department for four cross-sectional surveillance studies between 2006 and 2017. Participants completed a survey that assessed sociodemographic characteristics and behaviors, and cervicovaginal swabs were collected and tested for 36 HPV genotypes. We determined changes in proportions of non-vaccine-type HPV prevalence and conducted logistic regression to determine the odds of infection across the surveillance studies, propensity-score adjusted to control for selection bias. Analyses were stratified by vaccination status. Among vaccinated women who received only the 4-valent vaccine (n = 1,540), the adjusted prevalence of HPV types genetically related to HPV16 decreased significantly by 45.8% (adjusted odds ratio [AOR] = 0.48, 95% confidence interval [CI] = 0.31–0.74) from 2006–2017, demonstrating evidence of cross-protection. The adjusted prevalence of HPV types genetically related to HPV18 did not change significantly (14.2% decrease, AOR = 0.83, 95% CI = 0.56–1.21). The adjusted prevalence of HPV types genetically unrelated to vaccine types did not change significantly (4.2% increase, AOR = 1.09, CI = 0.80–1.48), demonstrating no evidence of type replacement. Further studies are needed to monitor for cross-protection and possible type replacement after introduction of the 9-valent HPV vaccine.

AB - Examination of cross-protection and type replacement after human papillomavirus (HPV) vaccine introduction is essential to guide vaccination recommendations and policies. The aims of this study were to examine trends in non-vaccine-type HPV: 1) genetically related to vaccine types (to assess for cross-protection) and 2) genetically unrelated to vaccine types (to assess for type replacement), among young women 13–26 years of age during the 11 years after HPV vaccine introduction. Participants were recruited from a hospital-based teen health center and a community health department for four cross-sectional surveillance studies between 2006 and 2017. Participants completed a survey that assessed sociodemographic characteristics and behaviors, and cervicovaginal swabs were collected and tested for 36 HPV genotypes. We determined changes in proportions of non-vaccine-type HPV prevalence and conducted logistic regression to determine the odds of infection across the surveillance studies, propensity-score adjusted to control for selection bias. Analyses were stratified by vaccination status. Among vaccinated women who received only the 4-valent vaccine (n = 1,540), the adjusted prevalence of HPV types genetically related to HPV16 decreased significantly by 45.8% (adjusted odds ratio [AOR] = 0.48, 95% confidence interval [CI] = 0.31–0.74) from 2006–2017, demonstrating evidence of cross-protection. The adjusted prevalence of HPV types genetically related to HPV18 did not change significantly (14.2% decrease, AOR = 0.83, 95% CI = 0.56–1.21). The adjusted prevalence of HPV types genetically unrelated to vaccine types did not change significantly (4.2% increase, AOR = 1.09, CI = 0.80–1.48), demonstrating no evidence of type replacement. Further studies are needed to monitor for cross-protection and possible type replacement after introduction of the 9-valent HPV vaccine.

KW - Cross-protection

KW - human papillomavirus

KW - type-replacement

UR - http://www.scopus.com/inward/record.url?scp=85068313485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068313485&partnerID=8YFLogxK

U2 - 10.1080/21645515.2018.1564438

DO - 10.1080/21645515.2018.1564438

M3 - Article

C2 - 30633598

AN - SCOPUS:85068313485

VL - 15

SP - 1962

EP - 1969

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 7-8

ER -